These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29143120)

  • 21. Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
    Yan H; Hu K; Wu W; Li Y; Tian H; Chu Z; Koeffler HP; Yin D
    PLoS One; 2016; 11(8):e0159954. PubMed ID: 27532268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development.
    Gao D; Han Y; Yang Y; Herman JG; Linghu E; Zhan Q; Fuks F; Lu ZJ; Guo M
    Epigenetics; 2017 Jul; 12(7):575-583. PubMed ID: 28678648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated analyses of multi-omics reveal global patterns of methylation and hydroxymethylation and screen the tumor suppressive roles of HADHB in colorectal cancer.
    Zhu Y; Lu H; Zhang D; Li M; Sun X; Wan L; Yu D; Tian Y; Jin H; Lin A; Gao F; Lai M
    Clin Epigenetics; 2018; 10():30. PubMed ID: 29507648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis.
    Du Y; Liu L; Wang C; Kuang B; Yan S; Zhou A; Wen C; Chen J; Wu Y; Yang X; Feng G; Liu B; Iwamoto A; Zeng M; Wang J; Zhang X; Liu H
    Oncotarget; 2016 Jul; 7(27):41885-41897. PubMed ID: 27248823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MPP3 inactivation by promoter CpG islands hypermethylation in colorectal carcinogenesis.
    Feng X; Chen K; Ye S; Wang H; Wei G; Tan W; Cheng S; Zhang Y; Liu S; Zhou Y
    Cancer Biomark; 2012; 11(2-3):99-106. PubMed ID: 23011156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer.
    Okugawa Y; Toiyama Y; Toden S; Mitoma H; Nagasaka T; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
    Gut; 2017 Jan; 66(1):107-117. PubMed ID: 26475630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA interference against TRIM29 inhibits migration and invasion of colorectal cancer cells.
    Xu W; Xu B; Yao Y; Yu X; Cao H; Zhang J; Liu J; Sheng H
    Oncol Rep; 2016 Sep; 36(3):1411-8. PubMed ID: 27430345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer.
    Tang JT; Wang JL; Du W; Hong J; Zhao SL; Wang YC; Xiong H; Chen HM; Fang JY
    Carcinogenesis; 2011 Aug; 32(8):1207-15. PubMed ID: 21665895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic inactivation and tumor-suppressor behavior of NGFR in human colorectal cancer.
    Yang Z; Chen H; Huo L; Yang Z; Bai Y; Fan X; Ni B; Fang L; Hu J; Peng J; Wang L; Wang J
    Mol Cancer Res; 2015 Jan; 13(1):107-19. PubMed ID: 25244921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
    Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
    J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-490-3p inhibits colorectal cancer metastasis by targeting TGFβR1.
    Xu X; Chen R; Li Z; Huang N; Wu X; Li S; Li Y; Wu S
    BMC Cancer; 2015 Dec; 15():1023. PubMed ID: 26714817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
    Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
    World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of miR-15b decreases cell migration and metastasis in colorectal cancer.
    Li J; Chen Y; Guo X; Zhou L; Jia Z; Tang Y; Lin L; Liu W; Ren C
    Tumour Biol; 2016 Jul; 37(7):8765-73. PubMed ID: 26743779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypermethylation-Associated Silencing of miR-125a and miR-125b: A Potential Marker in Colorectal Cancer.
    Chen H; Xu Z
    Dis Markers; 2015; 2015():345080. PubMed ID: 26693202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The high expression of long non-coding RNA PANDAR indicates a poor prognosis for colorectal cancer and promotes metastasis by EMT pathway.
    Lu M; Liu Z; Li B; Wang G; Li D; Zhu Y
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):71-81. PubMed ID: 27629879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Relevance of Plasma DNA Methylation in Colorectal Cancer Patients Identified by Using a Genome-Wide High-Resolution Array.
    Lin PC; Lin JK; Lin CH; Lin HH; Yang SH; Jiang JK; Chen WS; Chou CC; Tsai SF; Chang SC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1419-27. PubMed ID: 25472652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion.
    Cao B; Yang Y; Pan Y; Jia Y; Brock MV; Herman JG; Guo M
    Discov Med; 2013 Oct; 16(88):137-47. PubMed ID: 24099668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
    Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silencing speckle-type POZ protein by promoter hypermethylation decreases cell apoptosis through upregulating Hedgehog signaling pathway in colorectal cancer.
    Zhi X; Tao J; Zhang L; Tao R; Ma L; Qin J
    Cell Death Dis; 2016 Dec; 7(12):e2569. PubMed ID: 28032859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome.
    Pancione M; Sabatino L; Fucci A; Carafa V; Nebbioso A; Forte N; Febbraro A; Parente D; Ambrosino C; Normanno N; Altucci L; Colantuoni V
    PLoS One; 2010 Dec; 5(12):e14229. PubMed ID: 21151932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.